GC Medical Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GC Medical Science makes diagnostic reagents used to detect diseases such as HIV, hepatitis, tuberculosis, and malaria, as well as blood-glucose monitoring devices for diabetes management and dialysis fluids used in treating patients with chronic kidney failure.
Its products are supplied to hospitals, clinics, public health centres, and medical wholesale distributors across Korea. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the majority of its revenue from its diagnostic-reagent division, which spans immune, biochemical, and molecular diagnostics.
Summary is AI-generated and may contain errors · figures from DART filings
The company distributes diagnostic reagents from global partners including Germany's Diasys alongside its own products, broadening its portfolio beyond what most domestic peers offer.
GC Medical Science in five facts
What does GC Medical Science do?
GC Medical Science makes diagnostic reagents used to detect diseases such as HIV, hepatitis, tuberculosis, and malaria, as well as blood-glucose monitoring devices for diabetes management and dialysis fluids used in treating patients with chronic kidney failure.
Where is GC Medical Science listed and in which sector?
GC Medical Science (Korean name: 녹십자엠에스) trades under KRX code 142280 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is GC Medical Science?
Its market capitalisation was US$73.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GC Medical Science's latest annual revenue and operating profit?
For fiscal year 2025, GC Medical Science reported revenue of US$81.8M, operating profit of US$2.2M and net income of US$2.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 4.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
GC Medical Science filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$19.1M (−10.9% year on year), operating profit of US$523K (−29.8% year on year) and a net loss of US$2.84M (from a profit a year earlier).
Earnings · Jul 31 - Operating results (consolidated) (preliminary) (fair disclosure)
GC Medical Science filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$16.2M (−11.1% year on year), operating profit of US$201K (−41.1% year on year) and net income of US$152K (from a loss a year earlier).
Earnings · May 7 - Operating results (consolidated) (preliminary) (fair disclosure)Earnings · Jan 26
- [Amended] Supply contract signedSupply contract · Jan 23